RIPK2 inhibitor 3   Click here for help

GtoPdb Ligand ID: 10413

Synonyms: compound 3 [PMID: 31265286] | Example 1 [WO2014043446A1] | GSK2983559
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: This is an orally active RIPK2 inhibitor phosphate ester prodrug [1-2]. It is rapidly cleaved by alkaline phosphatases on contact with intestinal tissue and in whole blood. The prodrug formulation was designed to limit systemic exposure, and to focus activity at the preferred site of action in gut tissue.
A crystal structure of RIPK2 in complex with inhibitor 3 has been submitted to the PDB with ID 6RN8.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 9
Topological polar surface area 207.26
Molecular weight 538.07
XLogP 1.49
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OP(=O)(OCCOc1cc2ncnc(c2cc1S(=O)(=O)C(C)(C)C)Nc1ccc2c(c1)ncs2)O
Isomeric SMILES OP(=O)(OCCOc1cc2ncnc(c2cc1S(=O)(=O)C(C)(C)C)Nc1ccc2c(c1)ncs2)O
InChI InChI=1S/C21H23N4O7PS2/c1-21(2,3)35(29,30)19-9-14-15(10-17(19)31-6-7-32-33(26,27)28)22-11-23-20(14)25-13-4-5-18-16(8-13)24-12-34-18/h4-5,8-12H,6-7H2,1-3H3,(H,22,23,25)(H2,26,27,28)
InChI Key MJLYDVMFNHZMLV-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
This compound has been progressed to Phase 1 clinical evaluation for inflammatory bowel diseases (see NCT03358407). The research code used for the compound in this study is GSK2983559.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03358407 GSK2983559 First Time in Human Study Phase 1 Interventional GlaxoSmithKline